A medical miracle, but for how long?

AIDS Reader

Volumn 15, Issue 10, 2005, Pages

  Laurence, Jeffrey ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b American Foundation for AIDS Research (amfAR)   (United States)

^c AIDS Reader   (United States)

Author keywords

HAART; HIV AIDS; Immune reactivity; Opportunistic infection

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; CAUSE OF DEATH; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; EDITORIAL; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; KAPOSI SARCOMA; LONG TERM CARE; MEMORY T LYMPHOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PROGNOSIS; TUBERCULOSIS; VIRUS LOAD; IMMUNOLOGY; TIME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; TIME FACTORS;

EID: 27744449293     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Gazzard B. Antiretroviral therapy for HIV: medical miracles do happen. Lancet. 2005;366:346-347.
2. Sterne JA, Hernan MA, Ledergerber B, et al; Swiss Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-384.
3. Bonnet F, Lewden C, May T, et al; Mortalite 2000 Study Group. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis. 2005;37:482-487.
4. Laurence J. HPV-linked malignancy and the potential of vaccine-based prevention. AIDS Reader. 2005;15:3-4.
5. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS. 2005;19:1113-1124.
6. Kirk O, Reiss P, Uberti-Foppa C, et al; European HIV Cohorts. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med. 2002;137:239-250.
7. Martinon F, Michelet C, Peguillet I, et al. Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. AIDS. 1999;13:185-194.
8. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003;37:438-447.
9. + T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17:2015-2023.
10. Mauskopf J, Kitahata M, Kauf T, et al. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr. 2005;39:562-569.
11. Jansen CA, De Cuyper IM, Steingrover R, et al. Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS. 2005;19:1145-1154.
12. Veazey RS, Lackner AA. HIV swiftly guts the immune system. Nat Med. 2005;11:469-470.
13. + T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol. 2004;173:2184-2189.
14. + cells in HIV-1-infected patients receiving highly active anti-retroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis. 2005;191:1670-1679.
15. Dion ML, Poulin JF, Bordi R, et al. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity. 2004;21:757-768.
16. Kovacs JA, Lempicki RA, Sidorov IA, et al. Induction of prolonged survival of CD4 T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest. 2005;115:2139-2148.